{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:29:08Z","timestamp":1793942948945,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.radonc.2026.111827","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:55:56Z","timestamp":1791906956000},"page":"111827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Initial complete local therapy without systemic therapy versus systemic-therapy-based management in selected patients with oligometastatic renal cell carcinoma: a matched comparative study"],"prefix":"10.1016","volume":"225","author":[{"given":"Ha Un","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-4086","authenticated-orcid":false,"given":"Hye In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Kwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111827_b0005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111827_b0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111827_b0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111827_b0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111827_b0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111827_b0030","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111827_b0035","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2026.111827_b0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.radonc.2026.111827_b0055","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0060","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.25836","article-title":"Survival after complete surgical resection of multiple metastases from renal cell carcinoma","volume":"117","author":"Alt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111827_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JU.0000000000000488","article-title":"Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era","volume":"203","author":"Lyon","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111827_b0070","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.juro.2016.07.079","article-title":"Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"197","author":"Zaid","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111827_b0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic Ablative Radiation Therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111827_b0085","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.3390\/cancers16193276","article-title":"Stereotactic Body Radiotherapy (SBRT) for the treatment of primary localized renal cell carcinoma: a systematic review and meta-analysis","volume":"16","author":"Suleja","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111827_b0090","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.euf.2025.03.011","article-title":"Metastasis-directed therapy in the management of urothelial carcinoma: a systematic review and meta-analysis","volume":"11","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.radonc.2026.111827_b0095","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.radonc.2018.04.028","article-title":"Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two swedish centres 2005-2014","volume":"127","author":"Stenman","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.radonc.2026.111827_b0105","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer 2026 [Available from: https:\/\/www.nccn.org\/guidelines."},{"key":"10.1016\/j.radonc.2026.111827_b0110","article-title":"SABR for oligometastatic renal cell carcinoma","volume":"45","author":"David","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0115","article-title":"Initial and repeat metastasis-directed therapy in systemic therapy-na\u00efve oligometastatic renal cell carcinoma: oncologic outcomes and risk-based stratification","author":"Yu","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0120","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S1470-2045(25)00380-8","article-title":"Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial","volume":"26","author":"Tang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.12.007","article-title":"Stereotactic radiation for systemic therapy-na\u00efve oligometastatic kidney cancer: final results of a phase 2b trial","author":"Hannan","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clgc.2022.03.013","article-title":"Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: analysis of the REMARCC Registry","volume":"20","author":"Meagher","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.radonc.2026.111827_b0135","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant Pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111827_b0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","article-title":"Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma","volume":"87","author":"Bedke","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2026.111827_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02856","article-title":"Addition of metastasis-directed therapy to standard of care for oligometastatic disease: primary aggregated analysis of all baskets from the phase II randomized EXTEND trial","author":"Sherry","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111827_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16172963","article-title":"Predictive factors for long-term disease control in systemic treatment-na\u00efve oligorecurrent renal cell carcinoma treated with up-front stereotactic ablative radiotherapy (SABR)","volume":"16","author":"Franzese","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2026.111827_b0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:13:45Z","timestamp":1793942025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"alternative-id":["S0167814026006675"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111827","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial complete local therapy without systemic therapy versus systemic-therapy-based management in selected patients with oligometastatic renal cell carcinoma: a matched comparative study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111827"}}